14例肺原发性黏膜相关淋巴组织淋巴瘤疗效分析

目的 分析肺原发性黏膜相关淋巴组织淋巴瘤的临床特征和预后。方法 回顾分析1999—2012年间14例肺原发性黏膜相关淋巴组织淋巴瘤患者临床资料,其中Ⅰ_E期8例、Ⅱ_E期5例、Ⅲ_E期1例。4例单纯手术治疗,5例术后放疗或化疗,3例化放疗,2例单纯化疗。结果 中位年龄为55岁,男女之比为1∶1.33。中位随访时间为48.3个月。全组患者均存活,3例患者出现治疗失败。全组患者2、4年无进展生存率分别为91%和69%。治疗失败发生在疗后25~37个月,失败部位为双肺、纵隔淋巴结、右肺和脑膜。结论 肺原发黏膜相关淋巴组织淋巴瘤为惰性淋巴瘤,预后良好;临床上可根据患者病变范围和身体状况选择适当治疗。

Clinical features and treatment outcome of 14 patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma

Objective To analyze the clinical features and prognosis of patients with primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.Methods A retrospective analysis was performed on the clinical data of 14 patients with primary pulmonary MALT lymphoma between 1999 and 2012. Eight patients had Ann Arbor stage Ⅰ_E disease, 5 had stage Ⅱ_E disease, and 1 had stage Ⅲ_E disease. Overall, patients were treated with surgery alone (n=4), surgery followed by radiotherapy or chemotherapy (n=5), chemotherapy plus radiotherapy (n=3), or chemotherapy alone (n=2).Results The median age at diagnosis was 55 years. The male-to-female ratio was 1∶1.33. With a median follow-up of 48.3 months, no patient died during follow-up, but 3 patients had recurrence in the lungs, mediastinal lymph nodes, and right lung and meninges at 24.5, 28.5, and 36.5 months, respectively, after treatment. The 2- and 4-year progression-free survival rates were 91% and 69%, respectively.Conclusions Primary pulmonary MALT lymphoma is indolent, and most patients show a good response to treatment. Clinical treatment should be selected according to the lesion and patient's condition.